BioCentury
ARTICLE | Clinical News

Metadoxine ER: Phase III hold

October 17, 2016 7:00 AM UTC

FDA placed a full clinical hold on metadoxine ER to treat ADHD and fragile X syndrome, which affects the double-blind, placebo-controlled, international Phase III MEASURE trial in about 750 ADHD patie...